Genentech Pricing Strategy Is “Good For Society,” CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Levinson defends the high cost of targeted cancer treatments while suggesting the price of Avastin will increase.
You may also be interested in...
Avastin sBLA Submission Means Breast Cancer Pricing Could Be Set By November
Genentech is seeking a six-month priority review for bevacizumab in breast cancer.
Avastin sBLA Submission Means Breast Cancer Pricing Could Be Set By November
Genentech is seeking a six-month priority review for bevacizumab in breast cancer.
Amgen To Issue Biotech Cost-Effectiveness Study For Key Therapeutic Areas
The “Value of Biotechnology” study will examine the impact of biotech products on the social and economic burden of diseases such as asthma, stroke and diabetes.